Boston Scientific Corporation (BSX)
Last Price$104.91.0%
Market Cap$154.5B
BSX Rating
BSX Quality rating performance
BSX Intrinsic Value
Key Highlights:
As of Mar 03, 2025 BSX Relative Value is $53.7, which is overvalued by 48.8%, compared to current share price of $104.9.
As of Mar 03, 2025 BSX DCF Value is $14.4, which is overvalued by 86.3%, compared to current share price of $104.9.
BSX Share Price History
1W 0.5%
1M 1.7%
6M 29.2%
YTD 81.3%
1Y 55.5%
3Y 138.6%
5Y 181.7%
10Y 525.7%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
BSX Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$154.5B
$165.2B
$16.7B
$2,438.0M
Shares Outstanding
1,473M
Employees
53K
Growth (CAGR)
9.3%
13.4%
(23.60%)
14.5%
12.2%
122.46%
Profitability
67.0%
17.0%
11.0%
20.5%
14.6%
117.3%
Intrinsic Value
$34.2 (67.4% overvalued)
$14.7
$53.7
21.5%
Return on Capital
Financial Health
$10.7B
4.4x
9.3x
50.7%
Dividends
Earnings
Apr 22, 2025
BEAT by 4.0%
BEAT by 6.7%
(3.1%)
8 Beat & 2 Miss
BSX Stock Financials
BSX Income Statement Metrics
Annual
Quarterly
LTM
BSX Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$3,435.0M +37.2% YoY
Capital Expenditure (CAPEX)
($790.0M) +24.6% YoY
Free Cash Flow (FCF)
$2,645.0M +43.2% YoY
BSX Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$16.7B 17.6% YoY
Cost of revenue
$5,257.0M 21.0% YoY
Pre-tax income
$2,282.0M 15.0% YoY
13.6% margin
BSX Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$39.4B
Current assets ($6,920.0M, 17.6% of total)
$414.0M (1.1%)
$2,558.0M (6.5%)
Other current assets
$3,948.0M (10.0%)
Non-current assets ($32.5B, 82.4% of total)
$0.0 (0.0%)
$3,294.0M (8.4%)
$6,684.0M (17.0%)
Other non-current assets
$22.5B (57.1%)
Financial position
$10.3B
Cash & Short-term
Investments
Total Debt
BSX Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
BSX Earnings Surprises
Crunching data... Almost there!
BSX Dividends
BSX Dividend Yield
Crunching data... Almost there!
BSX Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with BSX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$154.5B | 6.7 | $34.2 67.4% overvalued | 55.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$242.4B | 7.0 | $174.5 24.5% undervalued | 19.2% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$150.5B | 6.6 | $305.1 22.7% overvalued | 12.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$120.9B | 6.2 | $114.6 21.5% undervalued | 14.7% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$43.4B | 6.1 | $54.1 24.2% overvalued | (18.0%) | $5,872.6M | $502.2M | 0.9% | 8.6% | 77.8% | 25.8% | 7.4% | |
$34.9B | 7.0 | $43.1 49.8% overvalued | (29.7%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$24.7B | 5.3 | $65.0 146.8% undervalued | 34.0% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$21.9B | 6.2 | $199.6 10.4% overvalued | (3.8%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.6B | 5.9 | $181.2 72.0% undervalued | (15.3%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$19.4B | 7.9 | $134.5 50.7% overvalued | 62.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$13.6B | 6.0 | $190.0 8.5% undervalued | (43.2%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
FAQ
What is Boston Scientific Corporation (BSX) stock rating?
As of today, Boston Scientific Corporation has a stock rating of 7 (out of 10), which is considered Good.
is Boston Scientific Corporation (BSX) a good stock to buy?
As of today, Boston Scientific Corporation has a Good stock rating, which is 67.4% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.